南方医科大学学报 ›› 2026, Vol. 46 ›› Issue (9): 2222-2229.doi: 10.12122/j.issn.1673-4254.2026.09.20
• • 上一篇
张娟娟1, 姚舒桓2, 赵祖源3, 孙香2, 朱紫茵2, 李丽2,4(
), 韦海涛4(
)
收稿日期:2026-01-26
出版日期:2026-09-20
发布日期:2026-09-30
通讯作者:
李丽,韦海涛
E-mail:10210051@vip.henu.edu.cn;taoge9885@163.com
作者简介:张娟娟、姚舒桓共同为第一作者基金资助:
Juanjuan ZHANG1, Shuhuan YAO2, Zuyuan ZHAO3, Xiang SUN2, Ziyin ZHU2, Li LI2,4(
), Haitao WEI4(
)
Received:2026-01-26
Online:2026-09-20
Published:2026-09-30
Contact:
Li LI, Haitao WEI
E-mail:10210051@vip.henu.edu.cn;taoge9885@163.com
摘要:
目的 系统比较八段锦、床旁功率自行车与吹气球训练对胸腔镜肺癌根治术后患者肺功能恢复效果。 方法 本研究为一项随机对照试验。于2021年1月~2022年6月,共纳入334例行胸腔镜肺癌根治术的患者,随机分为八段锦组(108例)、床旁功率自行车组(109例)与吹气球训练组(117例)。3组患者分别接受为期12周的指定方案训练,并于术后1 d(基线)、4周、12周、半年及1年系统评估其肺功能、运动耐力、呼吸困难程度、疼痛程度、免疫功能、有氧能力、生活质量及患者参与度。 结果 术后12周,3组患者各项观察指标均较基线水平获得显著改善(P<0.05)。组间比较结果显示,八段锦组在免疫功能指标(CD4+/CD8+比值、IgA及IgG水平)、疼痛程度、呼吸困难评分、生活质量评分及治疗参与度等方面的改善最为明显,均优于其他两组(P<0.05);床旁功率自行车组在第1秒用力呼气容积(FEV1)、6 min步行距离及峰值摄氧量(VO₂peak)方面的改善幅度显著大于吹气球训练组(P<0.05),而与八段锦组相比差异无统计学意义(P>0.05);吹气球训练组各项指标的改善程度整体较为有限。 结论 八段锦、床旁功率自行车与吹气球训练均为胸腔镜肺癌根治术后有效的康复方式,临床可结合患者的核心康复需求,为其提供针对性的个性化康复选择。
张娟娟, 姚舒桓, 赵祖源, 孙香, 朱紫茵, 李丽, 韦海涛. 八段锦、床旁功率自行车与吹气球训练对肺癌患者胸腔镜术后肺功能恢复效果的比较:一项随机对照试验[J]. 南方医科大学学报, 2026, 46(9): 2222-2229.
Juanjuan ZHANG, Shuhuan YAO, Zuyuan ZHAO, Xiang SUN, Ziyin ZHU, Li LI, Haitao WEI. Effects of Baduanjin, bedside cycle ergometer and balloon-blowing training on pulmonary function recovery following thoracoscopic surgery for lung cancer: a randomized controlled trial[J]. Journal of Southern Medical University, 2026, 46(9): 2222-2229.
| Variable | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | χ2/F | P |
|---|---|---|---|---|---|
| Age (year) | 63.20±8.14 | 62.71±7.86 | 63.84±7.51 | 0.643 | 0.526 |
| Gender (n) | 0.331 | 0.847 | |||
| Male | 61 | 59 | 68 | ||
| Female | 47 | 50 | 49 | ||
| BMI | 23.40±3.03 | 23.08±2.82 | 23.55±3.05 | 0.712 | 0.491 |
| Education level | 1.926 | 0.382 | |||
| High school or below | 65 | 70 | 76 | ||
| Junior college or above | 43 | 39 | 41 | ||
| Disease characteristics | |||||
| Disease course (years) | 5.21±2.12 | 4.92±2.25 | 5.40±2.05 | 1.245 | 0.289 |
| Pathological type | 0.894 | 0.925 | |||
| Squamous cell carcinoma | 31 | 29 | 35 | ||
| Adenocarcinoma | 72 | 75 | 77 | ||
| Other | 5 | 5 | 5 | ||
| Clinical stage | 1.557 | 0.817 | |||
| I | 71 | 74 | 75 | ||
| II | 31 | 29 | 35 | ||
| IIIa | 6 | 6 | 7 | ||
| Comorbidities | |||||
| Hypertension | 39 | 35 | 45 | 1.025 | 0.599 |
| Diabetes mellitus | 19 | 16 | 22 | 0.752 | 0.686 |
| Coronary heart disease | 11 | 9 | 13 | 0.522 | 0.770 |
| Smoking history | 0.385 | 0.825 | |||
| Yes | 57 | 62 | 63 | ||
| No | 51 | 47 | 54 | ||
| Surgery-related indicators | |||||
| Surgical method | 0.288 | 0.866 | |||
| Lobectomy | 90 | 92 | 99 | ||
| Segmentectomy | 18 | 17 | 18 | ||
| Operation time (min) | 89.83±5.22 | 88.50±6.06 | 90.11±4.99 | 0.412 | 0.663 |
| Intraoperative blood loss (mL) | 41.76±8.71 | 40.20±9.27 | 42.57±8.11 | 1.283 | 0.278 |
| Postoperative 24-hour drainage volume (mL) | 35.20±9.11 | 33.82±8.72 | 33.80±8.74 | 1.967 | 0.142 |
| Chest tube duration (days) | 1.56±0.53 | 1.57±0.64 | 1.77±0.40 | 1.445 | 0.237 |
| Postoperative hospital stay (days) | 3.61±1.15 | 3.52±1.16 | 3.83±0.99 | 2.342 | 0.098 |
表1 3组患者一般临床资料比较
Tab.1 Comparison of general clinical data among the 3 groups of patients
| Variable | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | χ2/F | P |
|---|---|---|---|---|---|
| Age (year) | 63.20±8.14 | 62.71±7.86 | 63.84±7.51 | 0.643 | 0.526 |
| Gender (n) | 0.331 | 0.847 | |||
| Male | 61 | 59 | 68 | ||
| Female | 47 | 50 | 49 | ||
| BMI | 23.40±3.03 | 23.08±2.82 | 23.55±3.05 | 0.712 | 0.491 |
| Education level | 1.926 | 0.382 | |||
| High school or below | 65 | 70 | 76 | ||
| Junior college or above | 43 | 39 | 41 | ||
| Disease characteristics | |||||
| Disease course (years) | 5.21±2.12 | 4.92±2.25 | 5.40±2.05 | 1.245 | 0.289 |
| Pathological type | 0.894 | 0.925 | |||
| Squamous cell carcinoma | 31 | 29 | 35 | ||
| Adenocarcinoma | 72 | 75 | 77 | ||
| Other | 5 | 5 | 5 | ||
| Clinical stage | 1.557 | 0.817 | |||
| I | 71 | 74 | 75 | ||
| II | 31 | 29 | 35 | ||
| IIIa | 6 | 6 | 7 | ||
| Comorbidities | |||||
| Hypertension | 39 | 35 | 45 | 1.025 | 0.599 |
| Diabetes mellitus | 19 | 16 | 22 | 0.752 | 0.686 |
| Coronary heart disease | 11 | 9 | 13 | 0.522 | 0.770 |
| Smoking history | 0.385 | 0.825 | |||
| Yes | 57 | 62 | 63 | ||
| No | 51 | 47 | 54 | ||
| Surgery-related indicators | |||||
| Surgical method | 0.288 | 0.866 | |||
| Lobectomy | 90 | 92 | 99 | ||
| Segmentectomy | 18 | 17 | 18 | ||
| Operation time (min) | 89.83±5.22 | 88.50±6.06 | 90.11±4.99 | 0.412 | 0.663 |
| Intraoperative blood loss (mL) | 41.76±8.71 | 40.20±9.27 | 42.57±8.11 | 1.283 | 0.278 |
| Postoperative 24-hour drainage volume (mL) | 35.20±9.11 | 33.82±8.72 | 33.80±8.74 | 1.967 | 0.142 |
| Chest tube duration (days) | 1.56±0.53 | 1.57±0.64 | 1.77±0.40 | 1.445 | 0.237 |
| Postoperative hospital stay (days) | 3.61±1.15 | 3.52±1.16 | 3.83±0.99 | 2.342 | 0.098 |
| Time point/Variable | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | |||||
| FEV1 (L) | 1.52±0.31 | 1.49±0.33 | 1.51±0.32 | 0.21 | 0.812 |
| FVC (L) | 2.18±0.41 | 2.15±0.43 | 2.17±0.42 | 0.15 | 0.861 |
| FEV1/FVC (%) | 69.81±5.20 | 69.33±5.52 | 69.60±5.29 | 0.24 | 0.787 |
| Postoperative 4 weeks | |||||
| FEV1 (L) | 1.78±0.33 | 1.85±0.35* | 1.71±0.32 | 4.12 | 0.017 |
| FVC (L) | 2.52±0.45 | 2.58±0.47 | 2.48±0.44 | 1.45 | 0.236 |
| FEV1/FVC (%) | 70.62±4.81 | 71.70±5.11* | 68.94±4.92 | 3.78 | 0.024 |
| Postoperative 12 weeks | |||||
| FEV1 (L) | 2.05±0.38* | 2.15±0.40* | 1.92±0.36 | 9.85 | <0.001 |
| FVC (L) | 2.85±0.50 | 2.91±0.52 | 2.79±0.49 | 1.92 | 0.148 |
| FEV1/FVC (%) | 71.90±4.51* | 73.79±4.70* | 68.84±4.62 | 12.34 | <0.001 |
| Postoperative six months | |||||
| FEV1 (L) | 2.11±0.39* | 2.21±0.41* | 1.98±0.37 | 8.15 | <0.001 |
| FVC (L) | 2.90±0.51 | 2.96±0.53 | 2.85±0.50 | 1.79 | 0.168 |
| FEV1/FVC (%) | 72.82±4.41* | 74.50±4.63* | 69.52±4.48 | 12.28 | <0.001 |
| Postoperative one year | |||||
| FEV1 (L) | 2.14±0.40* | 2.24±0.42* | 1.97±0.38 | 8.91 | <0.001 |
| FVC (L) | 2.93±0.52 | 3.00±0.54 | 2.86±0.51 | 1.96 | 0.142 |
| FEV1/FVC (%) | 73.02±4.31* | 74.73±4.51* | 68.91±4.42 | 14.01 | <0.001 |
表2 3组患者肺功能比较
Tab.2 Comparison of lung function among the 3 groups of patients (Mean±SD)
| Time point/Variable | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | |||||
| FEV1 (L) | 1.52±0.31 | 1.49±0.33 | 1.51±0.32 | 0.21 | 0.812 |
| FVC (L) | 2.18±0.41 | 2.15±0.43 | 2.17±0.42 | 0.15 | 0.861 |
| FEV1/FVC (%) | 69.81±5.20 | 69.33±5.52 | 69.60±5.29 | 0.24 | 0.787 |
| Postoperative 4 weeks | |||||
| FEV1 (L) | 1.78±0.33 | 1.85±0.35* | 1.71±0.32 | 4.12 | 0.017 |
| FVC (L) | 2.52±0.45 | 2.58±0.47 | 2.48±0.44 | 1.45 | 0.236 |
| FEV1/FVC (%) | 70.62±4.81 | 71.70±5.11* | 68.94±4.92 | 3.78 | 0.024 |
| Postoperative 12 weeks | |||||
| FEV1 (L) | 2.05±0.38* | 2.15±0.40* | 1.92±0.36 | 9.85 | <0.001 |
| FVC (L) | 2.85±0.50 | 2.91±0.52 | 2.79±0.49 | 1.92 | 0.148 |
| FEV1/FVC (%) | 71.90±4.51* | 73.79±4.70* | 68.84±4.62 | 12.34 | <0.001 |
| Postoperative six months | |||||
| FEV1 (L) | 2.11±0.39* | 2.21±0.41* | 1.98±0.37 | 8.15 | <0.001 |
| FVC (L) | 2.90±0.51 | 2.96±0.53 | 2.85±0.50 | 1.79 | 0.168 |
| FEV1/FVC (%) | 72.82±4.41* | 74.50±4.63* | 69.52±4.48 | 12.28 | <0.001 |
| Postoperative one year | |||||
| FEV1 (L) | 2.14±0.40* | 2.24±0.42* | 1.97±0.38 | 8.91 | <0.001 |
| FVC (L) | 2.93±0.52 | 3.00±0.54 | 2.86±0.51 | 1.96 | 0.142 |
| FEV1/FVC (%) | 73.02±4.31* | 74.73±4.51* | 68.91±4.42 | 14.01 | <0.001 |
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | 352.62±42.50 | 348.91±43.23 | 350.80±41.85 | 0.18 | 0.837 |
| Postoperative 4 weeks | 408.50±46.31 | 418.17±47.82* | 397.14±45.51 | 3.42 | 0.034 |
| Postoperative 12 weeks | 452.63±49.14* | 468.42±50.69* | 442.32±48.24 | 4.86 | 0.008 |
| Postoperative 6 months | 457.20±49.31* | 470.82±50.90* | 445.13±48.72 | 5.31 | 0.005 |
| Postoperative 1 year | 460.53±48.81* | 476.79±50.51* | 448.90±47.63 | 5.12 | 0.006 |
表3 3组患者运动耐力比较
Tab.3 Comparison of exercise endurance among the 3 groups of patients (Mean±SD)
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | 352.62±42.50 | 348.91±43.23 | 350.80±41.85 | 0.18 | 0.837 |
| Postoperative 4 weeks | 408.50±46.31 | 418.17±47.82* | 397.14±45.51 | 3.42 | 0.034 |
| Postoperative 12 weeks | 452.63±49.14* | 468.42±50.69* | 442.32±48.24 | 4.86 | 0.008 |
| Postoperative 6 months | 457.20±49.31* | 470.82±50.90* | 445.13±48.72 | 5.31 | 0.005 |
| Postoperative 1 year | 460.53±48.81* | 476.79±50.51* | 448.90±47.63 | 5.12 | 0.006 |
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | 5.24±1.31 | 5.30±1.40 | 5.40±1.31 | 0.45 | 0.639 |
| Postoperative 4 weeks | 2.93±1.10*△ | 3.23±1.24 | 3.62±1.29 | 4.32 | 0.014 |
| Postoperative 12 weeks | 1.64±0.93*△ | 2.09±1.04* | 2.61±1.13 | 5.87 | 0.003 |
| Postoperative 6 months | 1.49±0.80*△ | 2.04±0.92* | 2.49±1.02 | 5.43 | 0.005 |
| Postoperative 1 year | 1.38±0.79*△ | 1.87±0.91* | 2.42±1.04 | 5.12 | 0.006 |
表4 3组患者呼吸困难程度比较
Tab.4 Comparison of dyspnea severity among the 3 groups of patients (Mean±SD)
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | 5.24±1.31 | 5.30±1.40 | 5.40±1.31 | 0.45 | 0.639 |
| Postoperative 4 weeks | 2.93±1.10*△ | 3.23±1.24 | 3.62±1.29 | 4.32 | 0.014 |
| Postoperative 12 weeks | 1.64±0.93*△ | 2.09±1.04* | 2.61±1.13 | 5.87 | 0.003 |
| Postoperative 6 months | 1.49±0.80*△ | 2.04±0.92* | 2.49±1.02 | 5.43 | 0.005 |
| Postoperative 1 year | 1.38±0.79*△ | 1.87±0.91* | 2.42±1.04 | 5.12 | 0.006 |
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | 4.65±1.05 | 4.72±1.12 | 4.68±1.08 | 0.11 | 0.896 |
| Postoperative 4 weeks | 2.52±0.88* | 2.95±0.96 | 3.28±1.04 | 5.82 | 0.003 |
| Postoperative 12 weeks | 1.35±0.66*△ | 1.88±0.79* | 2.47±0.92 | 9.76 | <0.001 |
| Postoperative 6 months | 1.26±0.64*△ | 1.80±0.77* | 2.41±0.90 | 9.24 | <0.001 |
| Postoperative 1 year | 1.18±0.61*△ | 1.72±0.75* | 2.35±0.88 | 8.93 | <0.001 |
表5 3组患者疼痛程度比较
Tab.5 Comparison of pain severity among the 3 groups of patients (Mean±SD)
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | 4.65±1.05 | 4.72±1.12 | 4.68±1.08 | 0.11 | 0.896 |
| Postoperative 4 weeks | 2.52±0.88* | 2.95±0.96 | 3.28±1.04 | 5.82 | 0.003 |
| Postoperative 12 weeks | 1.35±0.66*△ | 1.88±0.79* | 2.47±0.92 | 9.76 | <0.001 |
| Postoperative 6 months | 1.26±0.64*△ | 1.80±0.77* | 2.41±0.90 | 9.24 | <0.001 |
| Postoperative 1 year | 1.18±0.61*△ | 1.72±0.75* | 2.35±0.88 | 8.93 | <0.001 |
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | |||||
| CD4+/CD8+ | 1.15±0.28 | 1.12±0.30 | 1.14±0.29 | 0.32 | 0.726 |
| IgA (g/L) | 1.92±0.45 | 1.88±0.47 | 1.90±0.46 | 0.25 | 0.779 |
| IgG (g/L) | 10.35±2.15 | 10.28±2.20 | 10.32±2.18 | 0.04 | 0.961 |
| Postoperative 4 weeks | |||||
| CD4+/CD8+ | 1.38±0.31* | 1.25±0.29 | 1.18±0.28 | 4.25 | 0.015 |
| IgA (g/L) | 2.18±0.43* | 2.05±0.41 | 1.92±0.39 | 3.98 | 0.020 |
| IgG (g/L) | 11.45±2.10* | 10.95±2.06 | 10.65±2.04 | 3.72 | 0.025 |
| Postoperative 12 weeks | |||||
| CD4+/CD8+ | 1.58±0.33*△ | 1.38±0.31* | 1.22±0.29 | 4.85 | 0.008 |
| IgA (g/L) | 2.48±0.45* | 2.22±0.43 | 2.05±0.41 | 4.52 | 0.012 |
| IgG (g/L) | 12.55±2.15*△ | 11.55±2.09* | 11.05±2.06 | 4.28 | 0.015 |
| Postoperative 6 months | |||||
| CD4+/CD8+ | 1.56±0.32*△ | 1.36±0.30* | 1.21±0.28 | 4.72 | 0.009 |
| IgA (g/L) | 2.46±0.44* | 2.20±0.42 | 2.03±0.40 | 4.41 | 0.013 |
| IgG (g/L) | 12.45±2.14*△ | 11.48±2.07* | 11.00±2.05 | 4.20 | 0.016 |
| Postoperative 1 year | |||||
| CD4+/CD8+ | 1.55±0.32*△ | 1.35±0.30* | 1.20±0.28 | 4.65 | 0.010 |
| IgA (g/L) | 2.45±0.44* | 2.18±0.42 | 2.02±0.40 | 4.35 | 0.014 |
| IgG (g/L) | 12.35±2.13*△ | 11.42±2.08* | 10.95±2.05 | 4.12 | 0.017 |
表6 3组患者免疫功能比较
Tab.6 Comparison of immune function among the 3 groups of patients (Mean±SD)
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | |||||
| CD4+/CD8+ | 1.15±0.28 | 1.12±0.30 | 1.14±0.29 | 0.32 | 0.726 |
| IgA (g/L) | 1.92±0.45 | 1.88±0.47 | 1.90±0.46 | 0.25 | 0.779 |
| IgG (g/L) | 10.35±2.15 | 10.28±2.20 | 10.32±2.18 | 0.04 | 0.961 |
| Postoperative 4 weeks | |||||
| CD4+/CD8+ | 1.38±0.31* | 1.25±0.29 | 1.18±0.28 | 4.25 | 0.015 |
| IgA (g/L) | 2.18±0.43* | 2.05±0.41 | 1.92±0.39 | 3.98 | 0.020 |
| IgG (g/L) | 11.45±2.10* | 10.95±2.06 | 10.65±2.04 | 3.72 | 0.025 |
| Postoperative 12 weeks | |||||
| CD4+/CD8+ | 1.58±0.33*△ | 1.38±0.31* | 1.22±0.29 | 4.85 | 0.008 |
| IgA (g/L) | 2.48±0.45* | 2.22±0.43 | 2.05±0.41 | 4.52 | 0.012 |
| IgG (g/L) | 12.55±2.15*△ | 11.55±2.09* | 11.05±2.06 | 4.28 | 0.015 |
| Postoperative 6 months | |||||
| CD4+/CD8+ | 1.56±0.32*△ | 1.36±0.30* | 1.21±0.28 | 4.72 | 0.009 |
| IgA (g/L) | 2.46±0.44* | 2.20±0.42 | 2.03±0.40 | 4.41 | 0.013 |
| IgG (g/L) | 12.45±2.14*△ | 11.48±2.07* | 11.00±2.05 | 4.20 | 0.016 |
| Postoperative 1 year | |||||
| CD4+/CD8+ | 1.55±0.32*△ | 1.35±0.30* | 1.20±0.28 | 4.65 | 0.010 |
| IgA (g/L) | 2.45±0.44* | 2.18±0.42 | 2.02±0.40 | 4.35 | 0.014 |
| IgG (g/L) | 12.35±2.13*△ | 11.42±2.08* | 10.95±2.05 | 4.12 | 0.017 |
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | 0.98±0.25 | 1.02±0.27 | 1.00±0.26 | 0.42 | 0.657 |
| Postoperative 4 weeks | 1.22±0.28 | 1.45±0.31* | 1.15±0.27 | 3.12 | 0.045 |
| Postoperative 12 weeks | 1.45±0.32* | 1.72±0.35*△ | 1.25±0.30 | 4.35 | 0.013 |
| Postoperative 6 months | 1.46±0.31* | 1.73±0.34*△ | 1.26±0.29 | 4.26 | 0.015 |
| Postoperative 1 year | 1.48±0.31* | 1.75±0.34*△ | 1.28±0.29 | 4.18 | 0.016 |
表7 3组患者有氧能力比较
Tab.7 Comparison of aerobic capacity among the 3 groups of patients (Mean±SD)
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | 0.98±0.25 | 1.02±0.27 | 1.00±0.26 | 0.42 | 0.657 |
| Postoperative 4 weeks | 1.22±0.28 | 1.45±0.31* | 1.15±0.27 | 3.12 | 0.045 |
| Postoperative 12 weeks | 1.45±0.32* | 1.72±0.35*△ | 1.25±0.30 | 4.35 | 0.013 |
| Postoperative 6 months | 1.46±0.31* | 1.73±0.34*△ | 1.26±0.29 | 4.26 | 0.015 |
| Postoperative 1 year | 1.48±0.31* | 1.75±0.34*△ | 1.28±0.29 | 4.18 | 0.016 |
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | 58.34±8.51 | 57.93±8.80 | 58.12±8.56 | 0.07 | 0.933 |
| Postoperative 4 weeks | 72.63±9.19* | 68.50±9.04 | 65.84±8.90 | 4.85 | 0.008 |
| Postoperative 12 weeks | 85.41±8.80*△ | 78.93±9.08* | 73.53±9.31 | 9.63 | <0.001 |
| Postoperative 6 months | 85.83±8.62*△ | 79.14±9.04* | 73.76±9.10 | 9.85 | <0.001 |
| Postoperative 1 year | 86.24±8.50*△ | 79.33±8.92* | 74.14±9.22 | 10.25 | <0.001 |
表8 3组患者生活质量比较
Tab.8 Comparison of quality of life among the 3 groups of patients (Mean±SD)
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | 58.34±8.51 | 57.93±8.80 | 58.12±8.56 | 0.07 | 0.933 |
| Postoperative 4 weeks | 72.63±9.19* | 68.50±9.04 | 65.84±8.90 | 4.85 | 0.008 |
| Postoperative 12 weeks | 85.41±8.80*△ | 78.93±9.08* | 73.53±9.31 | 9.63 | <0.001 |
| Postoperative 6 months | 85.83±8.62*△ | 79.14±9.04* | 73.76±9.10 | 9.85 | <0.001 |
| Postoperative 1 year | 86.24±8.50*△ | 79.33±8.92* | 74.14±9.22 | 10.25 | <0.001 |
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative 4 weeks | 92.50±6.81*△ | 85.32±9.21 | 78.61±11.50 | 8.95 | <0.001 |
| Postoperative 12 weeks | 88.69±8.22*△ | 79.23±10.57* | 72.44±13.82 | 12.34 | <0.001 |
| Postoperative 6 months | 87.52±8.91*△ | 78.04±11.50* | 70.91±14.48 | 11.62 | <0.001 |
| Postoperative 1 year | 86.34±9.50*△ | 76.82±12.33* | 69.54±15.23 | 10.87 | <0.001 |
表9 3组患者参与度比较
Tab.9 Comparison of participation among the 3 groups of patients (Mean±SD)
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative 4 weeks | 92.50±6.81*△ | 85.32±9.21 | 78.61±11.50 | 8.95 | <0.001 |
| Postoperative 12 weeks | 88.69±8.22*△ | 79.23±10.57* | 72.44±13.82 | 12.34 | <0.001 |
| Postoperative 6 months | 87.52±8.91*△ | 78.04±11.50* | 70.91±14.48 | 11.62 | <0.001 |
| Postoperative 1 year | 86.34±9.50*△ | 76.82±12.33* | 69.54±15.23 | 10.87 | <0.001 |
| [1] | Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-63. doi:10.3322/caac.21834 |
| [2] | Yan TD, Black D, Bannon PG, et al. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer[J]. J Clin Oncol, 2009, 27(15): 2553-62. doi:10.1200/jco.2008.18.2733 |
| [3] | Hong Q, Wang Y, Ma FY, et al. Patient-reported outcomes after lobectomy vs. segmentectomy for early-stage non-small cell lung cancer[J]. Surg Endosc, 2025, 39(11): 7566-75. doi:10.1007/s00464-025-12172-8 |
| [4] | 赖玉田, 王 娇, 李晓鸥, 等. 肺癌围手术期肺康复训练中国专家共识[J]. 中国肺癌杂志, 2024, 27(7): 495-503. |
| [5] | Xu JL, Li X, Zeng J, et al. Effect of Baduanjin Qigong on postoperative pulmonary rehabilitation in patients with non-small cell lung cancer: a randomized controlled trial[J]. Support Care Cancer, 2023, 32(1): 73. doi:10.1007/s00520-023-08194-4 |
| [6] | Oeser A, Messer S, Wagner C, et al. Cardiovascular training versus resistance training for fatigue in people with cancer[J]. Cochrane Database Syst Rev, 2024, 9(9): CD015519. doi:10.1002/14651858.cd015519.pub2 |
| [7] | 白 欢, 李 晶. 吹气球呼吸功能训练对肺癌患者术后康复效果及引流时间、引流量影响[J]. 医学食疗与健康, 2021, 19(10): 201-2. |
| [8] | Chen Y, Zhang P, Dong ZM, et al. Effect of Baduanjin exercise on health and functional status in patients with chronic obstructive pulmonary disease: a community-based, cluster-randomized controlled trial[J]. npj Prim Care Respir Med, 2024, 34: 43. doi:10.1038/s41533-024-00400-y |
| [9] | Ahmad AM, Abusarea SA, Fouad BZ, et al. Effect of adding early bedside cycling to inpatient cardiac rehabilitation on physical function and length of stay after heart valve surgery: a randomized controlled trial[J]. Arch Phys Med Rehabil, 2024, 105(6): 1050-7. doi:10.1016/j.apmr.2024.02.711 |
| [10] | 李景峰, 蒋天赐. 吹气球呼吸功能训练对肺癌患者术后肺功能及并发症的影响[J]. 深圳中西医结合杂志, 2023, 33(3): 119-22. |
| [11] | 国家体育总局健身气功管理中心. 健身气功·八段锦[M]. 北京: 人民体育出版社, 2003. |
| [12] | Scherr J, Wolfarth B, Christle JW, et al. Associations between Borg's rating of perceived exertion and physiological measures of exercise intensity[J]. Eur J Appl Physiol, 2013, 113(1): 147-55. doi:10.1007/s00421-012-2421-x |
| [13] | Zink EK, Kumble S, Beier M, et al. Physiological responses to in-bed cycle ergometry treatment in intensive care unit patients with external ventricular drainage[J]. Neurocritical Care, 2021, 35(3): 707-13. doi:10.1007/s12028-021-01204-5 |
| [14] | 刘国芳. 腹式呼吸训练+吹气球在哮喘慢性持续期患者康复护理中的应用[J]. 黑龙江医学, 2022, 46(20): 2518-20. |
| [15] | Heinicke G, Clay R, DeCato TW. Six-minute-walk testing[J]. Am J Respir Crit Care Med, 2021, 204(3): P5-6. doi:10.1164/rccm.2043p5 |
| [16] | Kendrick KR, Baxi SC, Smith RM. Usefulness of the modified 0-10 Borg scale in assessing the degree of dyspnea in patients with COPD and asthma[J]. J Emerg Nurs, 2000, 26(3): 216-22. doi:10.1016/s0099-1767(00)90093-x |
| [17] | Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain[J]. J Pain, 2003, 4(7): 407-14. doi:10.1016/s1526-5900(03)00716-8 |
| [18] | Jones LW, Watson D, Herndon II JE, et al. Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer[J]. Cancer, 2010, 116(20): 4825-32. doi:10.1002/cncr.25396 |
| [19] | 李 鲁, 王红妹, 沈 毅. SF-36健康调查量表中文版的研制及其性能测试[J]. 中华预防医学杂志, 2002, 36(2): 109-13. doi:10.3760/j:issn:0253-9624.2002.02.011 |
| [20] | Ma JL, Li XY, Zhao SF, et al. Robot-assisted thoracic surgery versus video-assisted thoracic surgery for lung lobectomy or segmentectomy in patients with non-small cell lung cancer: a meta-analysis[J]. BMC Cancer, 2021, 21(1): 498. doi:10.1186/s12885-021-08241-5 |
| [21] | Cavalheri V, Burtin C, Formico VR, et al. Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer[J]. Cochrane Database Syst Rev, 2019, 6(6): CD009955. doi:10.1002/14651858.cd009955.pub3 |
| [22] | Cavalheri V, Granger CL. Exercise training as part of lung cancer therapy[J]. Respirology, 2020, 25(S2): 80-7. doi:10.1111/resp.13869 |
| [23] | Abidi Y, Fekete M, Farkas Á, et al. Effectiveness and quality of life in lung cancer, pre-, post- and perioperative rehabilitation–A review[J]. PhysInt, 2023, 110(2): 89-107. doi:10.1556/2060.2023.00237 |
| [24] | Wu D, Li J, Dong H, et al. Effect of Baduanjin on postoperative activity tolerance, lung function and negative emotions in patients with lung cancer: a protocol for systematic review and meta-analysis[J]. BMJ Open, 2025,15(5): e093152. doi:10.1136/bmjopen-2024-093152 |
| [25] | Plinsinga ML, Singh B, Rose GL, et al. The effect of exercise on pain in people with cancer: a systematic review with meta-analysis[J]. Sports Med, 2023, 53(9): 1737-52. doi:10.1007/s40279-023-01862-9 |
| [26] | Wang X, Yin X, Liu P, et al. The effect of Baduanjin Qigong combined with five-elements music on anxiety and quality of sleep in asymptomatic patients with COVID-19 infection: a randomised controlled trial[J]. Heliyon, 2023, 9(8): e18962. doi:10.1016/j.heliyon.2023.e18962 |
| [27] | Oh B, Bae K, Lamoury G, et al. The effects of Tai Chi and Qigong on immune responses: a systematic review and meta-analysis[J]. Medicines, 2020, 7(7): 39. doi:10.3390/medicines7070039 |
| [28] | Scott JM, Thomas SM, Herndon JE 2nd, et al. Effects and tolerability of exercise therapy modality on cardiorespiratory fitness in lung cancer: a randomized controlled trial[J]. J Cachexia Sarcopenia Muscle, 2021, 12(6): 1456-65. doi:10.1002/jcsm.12828 |
| [29] | Sturzenegger N, Schneider SR, Furian M, et al. The effect of eccentric cycling on cerebral and muscle tissue oxygenation in patients with pulmonary hypertension and healthy individuals: a randomized controlled crossover trial[J]. J Clin Med, 2025, 14(16): 5751. doi:10.3390/jcm14165751 |
| [30] | Ulrich S, Kammerlander A, Schneider SR, et al. Effect of eccentric cycling on oxygen uptake and hemodynamics in patients with chronic obstructive pulmonary disease: a randomized controlled crossover trial[J]. Respiration, 2025, 104(9): 637-47. doi:10.1159/000545787 |
| [31] | Zisi D, Chryssanthopoulos C, Nanas S, et al. The effectiveness of the active cycle of breathing technique in patients with chronic respiratory diseases: a systematic review[J]. Heart Lung, 2022, 53: 89-98. doi:10.1016/j.hrtlng.2022.02.006 |
| [1] | 陈翠妍, 张文娴, 蔡依琳, 欧阳媚, 梁叶, 梁铭标, 梁会营. 基于机器学习算法构建老年患者肺功能智能评估模型[J]. 南方医科大学学报, 2026, 46(9): 2091-2100. |
| [2] | 董俊余, 郭佳俊, 李岱容, 杜永洪. 超声协同靶向纳米粒抑制乏氧肺癌细胞增殖、迁移及侵袭[J]. 南方医科大学学报, 2026, 46(6): 1278-1289. |
| [3] | 梁芷晴, 潘富珍, 邓利强, 麦哲芬, 马云, 施传坚, 付卫明. 生脉散通过调控乳酸/Wnt/β-catenin/LDHA通路改善非小细胞肺癌奥希替尼耐药的作用机制[J]. 南方医科大学学报, 2026, 46(3): 523-531. |
| [4] | 黄启智, 谢戴鹏, 姚霖彤, 李洽轩, 吴少伟, 周海榆. 肿瘤微环境特异性CT影像组学标签预测非小细胞肺癌免疫治疗疗效[J]. 南方医科大学学报, 2025, 45(9): 1903-1918. |
| [5] | 何丽君, 陈晓菲, 闫陈昕, 师林. 扶正化积汤治疗非小细胞肺癌的分子机制:基于网络药理学及体外实验验证[J]. 南方医科大学学报, 2025, 45(6): 1143-1152. |
| [6] | 王心恒, 邵小涵, 李童童, 张璐, 杨勤军, 叶卫东, 童佳兵, 李泽庚, 方向明. 平喘宁方通过调控HMGB1/Beclin-1轴介导的自噬改善患寒哮证大鼠的气道炎症[J]. 南方医科大学学报, 2025, 45(6): 1153-1162. |
| [7] | 李丹丹, 楚佳鑫, 闫妍, 徐文隽, 朱行春, 孙韵, 丁浩峰, 任丽, 朱博. 姜黄素通过下调HIF-1α通路抑制非小细胞肺癌脂质代谢[J]. 南方医科大学学报, 2025, 45(5): 1039-1046. |
| [8] | 钟娜, 王会杰, 赵文英, 孙珍贵, 耿彪. 高表达RNF7增强非小细胞肺癌细胞的PD-1耐药:基于活化NF-kB通路促进CXCL1表达和髓源性抑制细胞的募集[J]. 南方医科大学学报, 2024, 44(9): 1704-1711. |
| [9] | 陈桂玲, 廖晓凤, 孙鹏涛, 岑欢, 舒盛春, 李碧晶, 黎金华. 澳洲茄碱通过调控Bcl-2/Bax/caspase-3信号通路促进非小细胞肺癌发生凋亡[J]. 南方医科大学学报, 2024, 44(6): 1109-1116. |
| [10] | 李菲凡, 向俊馨, 刘佳慧, 王效静, 江浩. LncRNA FEZF1-AS1通过miR-130a-5p/CCND1轴促进非小细胞肺癌发展的分子机制研究[J]. 南方医科大学学报, 2024, 44(5): 841-850. |
| [11] | 杨 杨, 刘 刚, 欧 毅, 鹿文琪. 艾司氯胺酮联合肢体远端缺血预处理对胸腔镜下肺癌根治术老年患者有肺保护作用:160例随机对照试验[J]. 南方医科大学学报, 2024, 44(3): 484-490. |
| [12] | 韩齐齐, 叶梦然, 金齐力. 去甲泽拉木醛通过抑制 AKT/CREB 信号通路抑制非小细胞肺癌细胞的增殖、迁移和侵袭[J]. 南方医科大学学报, 2024, 44(2): 280-288. |
| [13] | 刘雪柔, 杨玉梅, 刘伟, 张振, 周星琦, 谢文宇, 申林, 张梦晓, 李娴, 臧家兰, 李姗姗. 中药泽漆抑制非小细胞肺癌细胞增殖、侵袭、迁移以及促进细胞凋亡[J]. 南方医科大学学报, 2024, 44(10): 1918-1925. |
| [14] | 周智锋, 柳硕岩, 李洁羽, 陈明秋, 林辉, 陈宇杰, 陈伟杰, 林军鹏, 周航, 郑庆丰. IL-21和CCL19修饰可提高NKP30 CAR-T细胞对肺癌的杀伤效率并促进其肿瘤浸润[J]. 南方医科大学学报, 2024, 44(10): 1926-1936. |
| [15] | 杨玉梅, 刘雪柔, 刘伟, 周星琦, 张振, 胡妍, 刘培培, 李娴, 刘浩, 李姗姗. 阿美替尼联合安罗替尼通过下调PI3K/AKT通路抑制非小细胞肺癌细胞的增殖[J]. 南方医科大学学报, 2024, 44(10): 1965-1975. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||